Evidence map›Paper›PMID 39209479›Full record

ArticleThe European respiratory journal2024

Exploring the patient perspective in pulmonary hypertension.

H James Ford, Colleen Brunetti, Pisana Ferrari, Gergely Meszaros, Victor M Moles, Hall Skaara, Adam Torbicki, J Simon R Gibbs

Abstract read
In one paragraph

Article in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Improving shared decision-making in bronchiectasis.BMJ open respiratory research · 2025
    Review
  19. The PAH patient's perspective.International journal of cardiology. Congenital heart disease · 2025
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

H James FordUniversity of North Carolina at Chapel Hill, Pulmonary Hypertension Program, Division of Pulmonary and Critical Care Medicine, Chapel Hill, NC, USA.ORCID https://orcid.org/0009-0003-2057-3914
Colleen BrunettiPulmonary Hypertension Association, Washington, DC, USA.
Pisana FerrariAlliance for Pulmonary Hypertension, Brussels, Belgium.
Gergely MeszarosEuropean Reference Network-Respiratory Diseases, Frankfurt, Germany.
Victor M MolesUniversity of Michigan, Pulmonary Hypertension Program, Division of Cardiovascular Medicine, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0002-9512-3825
Hall SkaaraPHA Europe, Vienna, Austria.
Adam TorbickiDepartment of Pulmonary Circulation, Center for Postgraduate Medical Education, ECZ-Otwock, ERN-Lung Member, Otwock, Poland adam.torbicki@ecz-otwock.pl.ORCID https://orcid.org/0000-0003-3475-8832
J Simon R GibbsNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-6147-9252

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global impacts of pulmonary hypertension (PH) were formally recognised in 1973 at the 1st World Health Organization meeting dedicated to primary pulmonary hypertension, held in Geneva. Investigations into disease pathogenesis and classification led to the development of numerous therapies over the ensuing decades. While the impacts of the disease have been lessened due to treatments, the symptoms and adverse effects of PH and its therapies on patients' wellbeing and mental health remain significant. As such, there is a critical need to enhance understanding of the challenges patients face on a global scale with respect to care access, multidimensional patient support and advocacy. In addition, thoughtful analysis of the potential benefits and utilisation of mechanisms for the incorporation of patient-reported outcomes into diagnosis and treatment plans is needed. A summary of these areas is included here. We present a report of global surveys of patient and provider experiences and challenges regarding care access and discuss possible solutions. Also addressed is the current state of PH patient associations around the world. Potential ways to enhance patient associations and enable them to provide the utmost support are discussed. A summary of relevant patient-reported outcome measures to assess health-related quality of life in PH is presented, with suggestions regarding incorporation of these tools in patient care and research. Finally, information on how current global threats such as pandemics, climate change and armed conflict may impact PH patients is offered, along with insights as to how they may be mitigated with advanced contingency planning.

Indexed as

Hypertension, PulmonaryPatient Reported Outcome MeasuresQuality of LifeHealth Services AccessibilityHumans

Identifiers

PMID39209479
PMCPMC11525333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.